A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors

A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies

(2017) Ankit C. Borisa et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer

(2017) Ana Alcaraz-Sanabria et al.   MOLECULAR CANCER THERAPEUTICS

Abstract 3008: Preclinical characterization of AMG 900, a pan-aurora kinase inhibitor, alone and in combination with taxanes in ovarian cancer

(2016) Ondrej Kalous et al.   CANCER RESEARCH

The Aurora kinase inhibitors in cancer research and therapy

(2016) Jonas Cicenas   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Multi-kinase inhibitors, AURKs and cancer

(2016) Jonas Cicenas et al.   MEDICAL ONCOLOGY

Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress

(2015) Gerald S. Falchook et al.   SEMINARS IN ONCOLOGY

Aurora Kinase Inhibitors: Current Status and Outlook

(2015) Vassilios Bavetsias et al.   Frontiers in Oncology

The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities and aneuploidy

(2015) Italia Anna Asteriti et al.   Oncotarget

Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study

(2014) P. Schoffski et al.   ANNALS OF ONCOLOGY

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

(2014) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Feedback control of chromosome separation by a midzone Aurora B gradient

(2014) O. Afonso et al.   SCIENCE

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

(2014) J F Seymour et al.   Blood Cancer Journal

AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53

(2013) Ondrej Kalous et al.   BREAST CANCER RESEARCH AND TREATMENT

AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models

(2013) Tammy L. Bush et al.   MOLECULAR CANCER THERAPEUTICS

Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure

(2012) Hielke J. Meulenbeld et al.   BJU INTERNATIONAL

Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis

(2011) Anna Yemelyanova et al.   MODERN PATHOLOGY

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

(2011) H. Beltran et al.   Cancer Discovery

Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

(2010) M. Payton et al.   CANCER RESEARCH

Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells

(2009) P. Kaestner et al.   MOLECULAR CANCER THERAPEUTICS

Sixteen-Kinase Gene Expression Identifies Luminal Breast Cancers with Poor Prognosis

(2008) P. Finetti et al.   CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER